Skip to main content
SpringerLink
Log in
Book cover

Geriatric Diseases pp 253–258Cite as

Immunoproliferative Disorders

  • Reference work entry
  • First Online:

  • 1555 Accesses

Abstract

Multiple myeloma (MM) is a B-cell neoplastic disease characterized by excessive number of abnormal plasma cells in the bone marrow and overproduction of intact monoclonal immunoglobulins or light chain (Bence Jones) proteins. The average age of onset is about 60 years and occurs more frequently in men than women. MM is preceded by a premalignant condition termed monoclonal gammopathy of undetermined significance (MGUS). Age is an important prognostic factor, and with each decade from the age of 50 years to over the age of 80, the overall survival declines. This review will provide an update on the clinical management of multiple myeloma.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   379.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   379.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Riedel DA, Pottern LM. The epidemiology of multiple myeloma. Haemat Oncol Clin North Am. 1992;6:225–47.

    CAS  Google Scholar 

  2. Kyle RA. Multiple myeloma: review of 869 cases. Mayo Clin Proc. 1975;50:29–40.

    CAS  PubMed  Google Scholar 

  3. Jagannath S. Pathophysiological underpinnings of multiple myeloma progression. J Managed Care Pharm Supplement. 2008;14(7):S7–S11.

    Article  Google Scholar 

  4. Katzel JA, Hari P, Vesole DH. Multiple myeloma: charging toward a bright future. CA Cancer J Clin. 2007;57:301–18.

    Article  PubMed  Google Scholar 

  5. Dimopoulos MA, Kastritis E, Rosinol L, Blake J, Ludwig H. Pathogenesis and treatment of renal failure in multiple myeloma bone disease. Haematol Oncol Clin North Am. 2007;21:1035-1-9.

    Google Scholar 

  6. Anderson KC,Carrasco RD. Pathogenesis of myeloma. Annual Rev Pathol Mech Dis. 2011;6:24.

    Article  Google Scholar 

  7. Kyle RA. “Benign” monoclonal gammopathy-after 20–35 years of follow up. Mayo Clin Proc. 1993;68:26–36.

    Article  CAS  PubMed  Google Scholar 

  8. Firkin F. Screening for multiple myeloma. Aust Prescriber. 2009;32:92–94.

    Article  Google Scholar 

  9. Ludwig H, Bolejack V, Crowley J, Blade J, San Miguel J, Kyle RA. Survival and years of life lost in different age cohorts of patients with multiple myeloma. J Clin Oncol. 2008;28:1599–160.

    Article  Google Scholar 

  10. Alexanian RA, Balcerzak S, Bonnet JD, Gehan E, Haut A, Hewlett JS, et al. Prognostic factors in multiple myeloma.Cancer.1975;36:1192–201.

    Article  CAS  PubMed  Google Scholar 

  11. Durrie BGM, Salmon SE, Moon TF. Pretreatment tumour mass, cell kinetics and prognosis in multiple myeloma. Blood. 1980;55:364–72.

    Google Scholar 

  12. Kyle RA. Prognostic factors in multiple myeloma. Stem Cells. 1995;13 Suppl. 2:56–63.

    PubMed  Google Scholar 

  13. Bataille R, Boccadoro M, Klein B, Durie B, Pileri A. C-Reactive protein and beta-2 microglobulin produce a simple powerful myeloma staging system. Blood 1992;80(3):733–7.

    CAS  PubMed  Google Scholar 

  14. Pelliniemi TT, Irjala K, Mattila K, PalkkiK, Rajamaki A, Tienhaara A, et al. Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Finnish Leukaemia Group. Blood. 1995;85(3):765–71.

    CAS  PubMed  Google Scholar 

  15. Durie BGM, Salmon SE. A clinical staging system for multiple myeloma. Cancer. 1975;36:842–854.

    Article  CAS  PubMed  Google Scholar 

  16. Greipp PR, Miguel JS, Durie BGM, Crawley JJ, Barlogie B, Blade J, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412–3420.

    Article  PubMed  Google Scholar 

  17. Cassuto JP, Krebs BJ, Vit G. Beta-2 microglobulin a tumour marker of lymphoproliferative disorders. Lancet. 1978;2:108–109.

    Article  CAS  PubMed  Google Scholar 

  18. Bataille R, Durrie BGM,Grenier J. Serum beta 2 microglobulin and similar markers in multiple myeloma : a reliable marker for staging. Br J Haematol. 1093;55:439–44.

    Google Scholar 

  19. Norfolk D,Child JA, Cooper EH, Kerruish S,Ward AM. Serum beta-2 microglobulin in myelomatosis. Potential value in stratification and monitoring. Br J Cancer. 1980;42(4):510–515.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Attal M, Haroussaue JL, Stoppa A M, Sotto JJ, Fuzibet JG, Rosal JF, et al. A prospective randomized trial of autologous bone marrow transplantation for multiple myeloma. Intergroupe Francais du Myeloma. N Engl J Med. 1996;335:91–97.

    Google Scholar 

  21. Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet J-O, et al. Intergroupe Francophone du Myelome. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med. 2004; 350:1655–1664.

    Article  Google Scholar 

  22. Hoarousseau J-L. Multiple myeloma in the elderly: When to treat. Whe to go to transplant. 2010. http://www.cancernetwork.com/mulitiple-myeloma/multiple-myeoma-elderly –when -treat.

  23. Osborn M, Horvath N, To LB. New drugs for multiple myeloma. Aust Prescriber. 2009;32:95–98.

    Article  Google Scholar 

  24. Joshua DE. Multiple myeloma: the present and the future. AJA. 2005;183:34418.

    Google Scholar 

  25. Attal M, Harousseau JL, Leyvraz S, Doyen C, Hulin C, Benbonbker L, et al. Maintenance treatment with thalidomide and pamidronate after autologous transplantation for myeloma: second analysis of a prospective randomized study of the Intergroupe Francophone du Myeloma. Haematologica. 2005;90 Suppl 1:17.

    Google Scholar 

  26. Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004:350:1655–1664.

    Article  CAS  PubMed  Google Scholar 

  27. Berenson JR, Rosen LS, Howell A, Porter L, Coleman RE, Morley N, et al. Zoledronic acid reduces skeletal –related events in patients with osteolytic metastases. Cancer. 2001;91:1191–1200.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The University of Sydney, Westmead Clinical School, Westmead, NSW, Australia

    Nages Nagaratnam & Kujan Nagaratnam

  2. Rehabilitation and Aged Care Service, Blacktown-Mt Druitt Hospital, Mount Druitt, NSW, Australia

    Gary Cheuk

Authors
  1. Nages Nagaratnam
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kujan Nagaratnam
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gary Cheuk
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Nagaratnam, N., Nagaratnam, K., Cheuk, G. (2018). Immunoproliferative Disorders. In: Geriatric Diseases. Springer, Cham. https://doi.org/10.1007/978-3-319-33434-9_25

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-33434-9_25

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-33433-2

  • Online ISBN: 978-3-319-33434-9

  • eBook Packages: MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation